The advent of PARP inhibitors, an increased use of laparoscopy for patient selection and a more prominent role of PROs have been facilitated by international collaborations
In this era of precision medicine, affordable profiling is essential
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.